[go: up one dir, main page]

ES2060685T3 - Medicamento con contenido de azelastina con liberacion controlada del principio activo. - Google Patents

Medicamento con contenido de azelastina con liberacion controlada del principio activo.

Info

Publication number
ES2060685T3
ES2060685T3 ES89106685T ES89106685T ES2060685T3 ES 2060685 T3 ES2060685 T3 ES 2060685T3 ES 89106685 T ES89106685 T ES 89106685T ES 89106685 T ES89106685 T ES 89106685T ES 2060685 T3 ES2060685 T3 ES 2060685T3
Authority
ES
Spain
Prior art keywords
azelastin
medication
content
active substance
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89106685T
Other languages
English (en)
Inventor
Helmut Dr Hettche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Application granted granted Critical
Publication of ES2060685T3 publication Critical patent/ES2060685T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Rotary Pumps (AREA)
  • Switches With Compound Operations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

MEDICAMENTOS CON ACELASTINA CON CESION CONTROLADA DE SUSTANCIAS ACTIVAS CON UTILIZACION DE UN COMPONENTE DE RETARDO, HABIENDO POR CADA PARTE DE PESO DE ACELASTINA (REFERIDO A LA BASE) 0,001 A 800 PARTES DE COMPONENTE DE RETARDO, PUDIENDO ESTAR LA ACELASTINA PRESENTE TAMBIEN EN FORMA DE SALES FISIOLOGICAMENTE INOFENSIVAS. LA VELOCIDAD DE LIBERACION DE ACELASTINA ESTA ENTRE 0,05 Y 5 MG POR HORA.
ES89106685T 1988-04-20 1989-04-14 Medicamento con contenido de azelastina con liberacion controlada del principio activo. Expired - Lifetime ES2060685T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3813244 1988-04-20

Publications (1)

Publication Number Publication Date
ES2060685T3 true ES2060685T3 (es) 1994-12-01

Family

ID=6352451

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89106685T Expired - Lifetime ES2060685T3 (es) 1988-04-20 1989-04-14 Medicamento con contenido de azelastina con liberacion controlada del principio activo.

Country Status (15)

Country Link
EP (1) EP0338444B1 (es)
JP (1) JP2950845B2 (es)
AT (1) ATE97572T1 (es)
AU (1) AU3318389A (es)
CA (1) CA1325976C (es)
DE (1) DE58906232D1 (es)
DK (1) DK172235B1 (es)
ES (1) ES2060685T3 (es)
FI (1) FI891865A7 (es)
HK (1) HK134494A (es)
HU (1) HU202403B (es)
IE (1) IE62778B1 (es)
MC (1) MC2025A1 (es)
PT (1) PT90308B (es)
ZA (1) ZA892877B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
DE4207234A1 (de) * 1992-03-07 1993-09-09 Asta Medica Ag Neue aminocarbonsaeure-derivate mit antiallergischer/antiasthmatischer wirkung und verfahren zu deren herstellung
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
JP4138910B2 (ja) 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
HU230454B1 (hu) 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001032148A1 (en) 1999-10-29 2001-05-10 Euro-Celtique, S.A. Controlled release hydrocodone formulations
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
JP2006523613A (ja) * 2002-12-20 2006-10-19 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ 徐放性医薬投与のための被覆粒子
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
WO2014153541A1 (en) 2013-03-21 2014-09-25 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
RU2018119121A (ru) 2015-10-27 2019-11-28 Юпраксия Фармасьютикалз Инк. Лекарственные формы местных анастетиков с замедленным высвобождением

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3575135D1 (de) * 1984-09-14 1990-02-08 Asta Pharma Ag Substituierte benzylphthalazinon-derivate.

Also Published As

Publication number Publication date
PT90308B (pt) 1994-10-31
DK172235B1 (da) 1998-02-02
ZA892877B (en) 1989-12-27
DK189189D0 (da) 1989-04-19
DK189189A (da) 1989-10-21
EP0338444B1 (de) 1993-11-24
JP2950845B2 (ja) 1999-09-20
HUT49808A (en) 1989-11-28
HU202403B (en) 1991-03-28
IE891263L (en) 1989-10-20
CA1325976C (en) 1994-01-11
EP0338444A1 (de) 1989-10-25
FI891865A0 (fi) 1989-04-19
MC2025A1 (fr) 1990-04-25
HK134494A (en) 1994-12-09
FI891865L (fi) 1989-10-21
PT90308A (pt) 1989-11-10
DE58906232D1 (de) 1994-01-05
FI891865A7 (fi) 1989-10-21
JPH01311024A (ja) 1989-12-15
ATE97572T1 (de) 1993-12-15
IE62778B1 (en) 1995-02-22
AU3318389A (en) 1989-10-26

Similar Documents

Publication Publication Date Title
ES2060685T3 (es) Medicamento con contenido de azelastina con liberacion controlada del principio activo.
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
DE3681582D1 (de) Pharmazeutische zubereitung mit abgabeeigenschaften.
ES2054818T3 (es) Dispositivo mejorado para el suministro transdermal de farmacos.
BR9812001A (pt) Composição farmacêutica para combinação de descongestionante piperidinoalcanol
ES2150425T3 (es) Linsidomina para el tratamiento de disfunciones erectiles.
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
DK270088D0 (da) Transdermal terapeutisk system, samt anvendelse og fremstilling deraf
FI920026A0 (fi) Farmaceutisk komposition anvaendbar som avmagringsmedicin.
FI875533L (fi) Insulinpreparat foer non-parenteral dosering.
ZA888461B (en) Azelastine-containing medicaments for application in the nose and/or at the eye
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
ES2067250T3 (es) Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion.
YU156788A (en) Process for producing matrix for releasing and/or dosing healing active material
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
DK324687A (da) Transdermalt farmeceutisk praeparat
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
MY107420A (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances.
YU36401A (sh) Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem
CO4920200A1 (es) Empaques farmaceuticos para ayudar o aumentar el cumplimien- to en la administracion de un regimen complejo de droga por via oral y metodos para su utilizacion
DE3773893D1 (de) Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika.
BR0107881A (pt) Uso de fsh tratamento de infertilidade
ES296841Y (es) Dispositivo de protesis estabilizadora.
ES2053683T3 (es) Forma de medicamento de aplicacion oral para el tratamiento de la hipertension una vez al dia con hidrocloruro de diltiazem.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 338444

Country of ref document: ES